

December 8, 2025

Company SanBio Co., Ltd.

name: (Code: 4592 TSE Growth)

Name of Keita Mori, Representative Director

representative: and President


For inquiries, Yoshihiro Kakutani, Corporate Officer

contact: of Management Administration

(Phone: 03-6264-3481)

<u>Appointment of Two Corporate Officers in the Quality Compliance</u> <u>& Regulatory Affairs Division and the Production Division</u>

SanBio Co., Ltd. hereby provides on this matter as per the attached document.





Appointment of Two Corporate Officers in the Quality Compliance & Regulatory Affairs Division and the Production Division

SanBio Co., Ltd. (Head office: Chuo-ku, Tokyo, Representative Director and President: Keita Mori, hereinafter, the "Company") announces that it has welcomed Soyoku Nobeyama as Corporate Officer, Head of the Quality Compliance & Regulatory Affairs Division, and Tetsuya Isono as Corporate Officer, Head of the Production Division.

Mr. Nobeyama has built a wide-ranging career in R&D and quality assurance at global pharmaceutical companies, where he led evaluations of in-licensing candidates, planning and execution of development strategies, regulatory approval filings, and post-marketing lifecycle management. At CSL Behring K.K., he served as a Corporate Officer, Head of Regulatory Affairs, and Marketing Supervisor–General. He also focused on organizational and talent development as a member of domestic and global leadership teams, contributing to strengthening capabilities of multidisciplinary teams and building a sustainable organization.

Mr. Isono was engaged in process development for biologics drug substances and clinical trial drug manufacturing at Chugai Pharmaceutical Co., Ltd., contributing to obtaining global marketing approval for multiple in-house developed products. He later served as Plant Manager of the Utsunomiya Plant at Chugai Pharma Manufacturing Co., Ltd., where he established a robust and stable production and supply system for biologics drug substances and drug products manufactured for global markets. He has long been committed to nurturing biopharmaceutical talent, and through collaboration with stakeholders both inside and outside the industry, has continued to contribute to developing the next generation of leaders for Japan's biopharmaceutical industry.

SanBio received conditional and time-limited approval for AKUUGO® Suspension for Intracranial Implantation ("AKUUGO®") from the Ministry of Health, Labour and Welfare in July 2024. In October 2025, the Pharmaceutical Affairs and Food Sanitation Council's Regenerative Medicine and Biologics Subcommittee concluded that it had no objection to partial changes to the terms of approval of AKUUGO®. Toward the product's launch, the Company aims to strengthen its manufacturing and quality assurance systems to ensure a stable supply in Japan. Leveraging Mr. Nobeyama's extensive experience in quality assurance and Mr. Isono's broad expertise in pharmaceutical manufacturing, the Company will work to establish a robust domestic distribution and supply structure that will also reinforce the foundation for future expansion into the United States, thereby advancing initiatives to maximize corporate value.

Upon assuming the position of Corporate Officer, Mr. Nobeyama commented as follows:

"To ensure that regenerative medicine becomes a true source of hope for patients, I will dedicate myself to building unwavering reliability across all aspects of quality, safety, and regulatory affairs. I am fully committed to delivering AKUUGO® and SanBio's other innovative treatments to patients as soon as possible." Mr. Isono made the following comments: "Under SanBio's mission to become a global leader in regenerative medicine, I'm determined, as Head of the Production Division, to fulfill our steadfast responsibility to deliver the world's first cellular therapy to patients. While pursuing global standards of quality and GMP, I will work to establish a resilient supply system to deliver SanBio's innovative medicines swiftly and reliably to patients in need around the world."

Representative Director and President Keita Mori added the following: "We are extremely pleased to welcome Mr. Nobeyama, with his long-standing experience and proven track records in quality assurance, and Mr. Isono, with his many years of experience and accomplishments in pharmaceutical manufacturing. Their extensive expertise and capabilities are essential to delivering our Group's regenerative medicine products safely and reliably to a growing number of patients, and I'm confident they will be a major driving force in the continued development of our Group.

About SanBio

SanBio was founded in California, the US in 2001 with the vision of becoming a global leader in the field of regenerative medicine and is engaged in the regenerative cell business—we research, develop, manufacture, and sell regenerative cell medicines. On July 31 2024, under the Sakigake Designation Program, we obtained conditional and time-limited approval for our mainstay product AKUUGO® for the indication of improving chronic motor paralysis associated with traumatic brain injury. Going forward, we will continue focusing our R&D efforts on central nervous system disorders with significant unmet medical needs that cannot be addressed by existing medicine or drugs. The Company is headquartered in Tokyo, Japan and Oakland, California, and additional information about SanBio Group is available at https://sanbio.com/en/

For more information, contact:

SanBio Co., Ltd.

Management Administration
Email: info@sanbio.com